All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Arbutus Biopharma Corp. has described programmed cell death 1 ligand 1 (PD-L1) antagonists reported to be useful for the treatment of cancer, hepatitis B and hepatitis D viral infection.
